Literature DB >> 11274991

Interaction of the neuroprotective drug riluzole with GABA(A) and glycine receptor channels.

B Mohammadi1, K Krampfl, H Moschref, R Dengler, J Bufler.   

Abstract

Riluzole is used as therapeutic agent in amyotrophic lateral sclerosis. We investigated the interaction of riluzole with recombinant GABA (gamma-aminobutyric acid)(A) receptor channels (alpha(1)beta(2)gamma(2)-subunits) and glycine receptor channels (alpha(1)beta-subunits) transiently expressed in HEK293 cells. For electrophysiological experiments, the patch-clamp technique in combination with tools for ultrafast solution exchange was used. Saturating concentrations of GABA or glycine were applied with different concentrations of riluzole to outside-out patches containing alpha(1)beta(2)gamma(2) GABA(A) receptor channels or alpha(1)beta-glycine receptor channels on their surface, respectively. The current declined after application of GABA or glycine with three time constants of desensitization to a steady-state current amplitude. Application of riluzole resulted in a shift to fast desensitized states at both receptors. The proportion of the time constants of fast desensitization increased and the time constants of slow desensitization and the steady-state current decreased whereas the maximal current amplitudes were not affected by riluzole. The data of the study demonstrate for the first time interaction of GABAergic and glycinergic currents with riluzole under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274991     DOI: 10.1016/s0014-2999(01)00847-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Kinetic analysis of recombinant mammalian alpha(1) and alpha(1)beta glycine receptor channels.

Authors:  B Mohammadi; K Krampfl; C Cetinkaya; H Moschref; J Grosskreutz; R Dengler; J Bufler
Journal:  Eur Biophys J       Date:  2003-02-19       Impact factor: 1.733

2.  Patterns of cortical activity differ in ALS patients with limb and/or bulbar involvement depending on motor tasks.

Authors:  Katja Kollewe; Thomas F Münte; Amir Samii; Reinhard Dengler; Susanne Petri; Bahram Mohammadi
Journal:  J Neurol       Date:  2010-12-03       Impact factor: 4.849

3.  Two mechanisms of action of the adamantane derivative IEM-1460 at human AMPA-type glutamate receptors.

Authors:  Friedrich Schlesinger; Derk Tammena; Klaus Krampfl; Johannes Bufler
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

4.  Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABA(A)-receptors.

Authors:  K Jahn; F Schlesinger; L J Jin; R Dengler; J Bufler; K Krampfl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-06       Impact factor: 3.000

5.  Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.

Authors:  J Marc Simard; Orest Tsymbalyuk; Kaspar Keledjian; Alexander Ivanov; Svetlana Ivanova; Volodymyr Gerzanich
Journal:  Exp Neurol       Date:  2011-12-08       Impact factor: 5.330

Review 6.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 7.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; John H Krystal; Vladimir Coric
Journal:  NeuroRx       Date:  2006-01

8.  Glycinergic innervation of motoneurons is deficient in amyotrophic lateral sclerosis mice: a quantitative confocal analysis.

Authors:  Qing Chang; Lee J Martin
Journal:  Am J Pathol       Date:  2008-12-30       Impact factor: 4.307

9.  Persistent Sodium Current Drives Excitability of Immature Renshaw Cells in Early Embryonic Spinal Networks.

Authors:  Juliette Boeri; Hervé Le Corronc; François-Xavier Lejeune; Barbara Le Bras; Christine Mouffle; Monara Kaelle S C Angelim; Jean-Marie Mangin; Pascal Branchereau; Pascal Legendre; Antonny Czarnecki
Journal:  J Neurosci       Date:  2018-07-16       Impact factor: 6.167

10.  The Sur1-Trpm4 Channel in Spinal Cord Injury.

Authors:  J Marc Simard; Seung Kyoon Woo; Bizhan Aarabi; Volodymyr Gerzanich
Journal:  J Spine       Date:  2013-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.